Takeda plans to shell out $5.2 billion for the kind of deal most major drugmakers want: Ariad, its leukemia drug Iclusig and a pipeline with near-term…

In 2017's first issue of FiercePharmaAsia weekly wrap-up, Takeda spends $35 million on a GI deal, Ascletis is armed with $100 million in the country'…

Sun Pharma is dealing with the aftermath of a fire at an API plant in Ahmednagar that killed two and injured two others.

​​​​​​​Sanofi's promotional efforts for Dengvaxia have taken a hit in the Philippines.

In this week's FiercePharmaAsia wrap-up, Japan will likely update its drug pricing reviews’ timetable, Pfizer is selling a plant in Pakistan, and Perrigo…

Pfizer is negotiating the sale of manufacturing plant in Karachi to Pakistan drugmaker ICI Pakistan.

Japan’s unconventional timing of the Opdivo price cut might just be the prelude to a permanent change to the country’s drug review timeline, as the Shinzo Abe…

Perrigo, which is under pressure from investors to shore up its finances, will raise a little cash with a deal to sell an API plant to India’s Strides Shasun.

In this week's FiercePharmaAsia wrap-up, Takeda and VC Lightstone have joined forces in forming a neuroscience startup, China's cancer research is…

Pharma Asia